Baxano Surgical Inc  

(Public, NASDAQ:BAXS)   Watch this stock  
Find more results for NASDAQ:TSON
2.28
-0.02 (-0.87%)
Jun 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.26 - 2.33
52 week 1.55 - 3.40
Open 2.30
Vol / Avg. 47,534.00/69,931.00
Mkt cap 62.29M
P/E     -
Div/yield     -
EPS -1.14
Shares 27.32M
Beta 0.63
Inst. own 57%
Aug 5, 2013
Q2 2013 TRANS1 INC Earnings Release Add to calendar
May 9, 2013
Q1 2013 TRANS1 INC Earnings Conference Call
May 6, 2013
Q1 2013 TRANS1 INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -229.11% -205.13%
Operating margin -229.04% -204.12%
EBITD margin - -139.16%
Return on average assets -98.55% -69.27%
Return on average equity -160.43% -84.62%
Employees 89 -
Carbon Disclosure Rating - -

Address

Suite 230 110 Horizon Drive
RALEIGH, NC 27615
United States - Map
+1-919-8000020 (Phone)
+1-800-2535177 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Baxano Surgical Inc, formerly TranS1 Inc., is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region. It develops its pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising important surrounding soft tissue, nerves and bone structures. As of December 31, 2011, the Company was marketing the AxiaLIF family of products for single and multilevel lumbar fusion, the Vectre and Avatar lumbar posterior fixation systems and Bi-Ostetic bone void filler, a biologics product. All of the Company�s AxiaLIF products are delivered using its pre-sacral approach. It generates revenue from the sales of itsimplants and disposable surgical instruments. It has two distinct sales methods.

Officers and directors

Paul A. LaViolette Independent Chairman of the Board
Bio & Compensation  - Reuters
Kenneth Reali President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Joseph P. Slattery Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Greg Welsh Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Rick Feiler Vice President - Marketing
Age: 52
Bio & Compensation  - Reuters
Stephanie M. Fitts Ph.D. Vice President - Regulatory, Quality and Compliance
Bio & Compensation  - Reuters
Stephen D. Ainsworth Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Mukesh Ramchandani Vice President - Business and Market Development
Age: 46
Bio & Compensation  - Reuters
Russell C. Hirsch M.D., Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Mark T. Stautberg Director
Age: 53
Bio & Compensation  - Reuters